A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 37, Issue 11, Pages 1406-1414
Publisher
Wiley
Online
2017-09-12
DOI
10.1002/phar.2027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair
- (2017) Chun-Chin Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies
- (2016) Luc Dirix et al. CLINICAL THERAPEUTICS
- Therapeutic management of bone metastasis in prostate cancer: an update
- (2016) Fable Zustovich et al. Expert Review of Anticancer Therapy
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- (2016) J. Mateo et al. Targeted Oncology
- Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
- (2015) Ryan Stuchbery et al. CURRENT CANCER DRUG TARGETS
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
- (2015) Elena Castro et al. EUROPEAN UROLOGY
- Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
- (2015) Alessandra Modena et al. Expert Review of Anticancer Therapy
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
- (2014) O. S. Chao et al. MOLECULAR CANCER RESEARCH
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens
- (2013) Fred Saad et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
- (2013) Harrison et al. Cancer Management and Research
- Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
- (2012) Jatinder Goyal et al. CANCER LETTERS
- Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
- (2012) Himisha Beltran et al. EUROPEAN UROLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
- (2011) Yuan Yuan et al. Journal of Hematology & Oncology
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Expanding Treatment Options for Metastatic Prostate Cancer
- (2011) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunotherapy: Sipuleucel-T and Beyond
- (2011) Aimee E Hammerstrom et al. PHARMACOTHERAPY
- 405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments
- (2010) J.E. Ang et al. EJC SUPPLEMENTS
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now